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Toll-like receptors TLR7 and TLR9 are both implicated in the activation of autoreactive B
cells and other cell types associated with systemic lupus erythematosus (SLE)
pathogenesis. However, Tlr9–/– autoimmune-prone strains paradoxically develop more
severe disease. We have now leveraged the negative regulatory role of TLR9 to develop an
inducible rapid-onset murine model of systemic autoimmunity that depends on T cell
detection of a membrane-bound OVA fusion protein expressed by MHC class II+ cells,
expression of TLR7, expression of the type I IFN receptor, and loss of expression of TLR9.
These mice are distinguished by a high frequency of OVA-specific Tbet+, IFN-g+, and FasL-
expressing Th1 cells as well as autoantibody-producing B cells. Unexpectedly, contrary to
what occurs in most models of SLE, they also developed skin lesions that are very similar to
those of human cutaneous lupus erythematosus (CLE) as far as clinical appearance,
histological changes, and gene expression. FasL was a key effector mechanism in the skin,
as the transfer of FasL-deficient DO11gld T cells completely failed to elicit overt skin lesions.
FasL was also upregulated in human CLE biopsies. Overall, our model provides a relevant
system for exploring the pathophysiology of CLE as well as the negative regulatory role of
TLR9.
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Introduction
Cutaneous lupus erythematosus (CLE) refers to dermatologic fea-
tures of systemic lupus erythematosus (SLE) that may or may not 
be associated with more systemic manifestations, such as arthri-
tis, nephritis, or neurological disorders (1, 2). The most common 
cutaneous lesions in CLE patients are characterized histologically 
as interface dermatitis associated with epidermal basal-cell dam-
age, apoptosis of keratinocytes (KCs), and a variable subepithe-
lial inflammatory infiltrate in the skin that includes cytotoxic Th1 
cells and plasmacytoid dendritic cells (pDCs) (2–5). Common 
pathophysiological mechanisms, including proinflammtory type 
1 IFN, are thought to promote CLE and other clinical manifesta-
tions of SLE (7). Therefore, a better understanding of the genetic, 
environmental, and immunoregulatory factors that drive CLE 
is likely to provide important insights for the treatment of both 
CLE and SLE. However, remarkably little is known about the 
mechanisms that distinguish the different subcategories of CLE 
or cause CLE patients to progress to SLE, in part due to the lack of 
appropriate animal models. MRL/lpr is the most commonly stud-
ied strain in this context (8), but the onset of cutaneous disease 
in MRL/lpr mice is highly variable, is colony dependent, lacks a 
number of the key features of human CLE, and takes 6 months or 
more to develop.
There is a general consensus that environmental factors trig-
ger autoimmune disease in genetically predisposed individuals. 
These environmental triggers are often associated with tissue 
damage, followed by failure to effectively clear cell debris. The 
excessive accumulation of debris is detected by innate immune 
sensors and eventually leads to a break in self-tolerance. Studies 
from our group and others have strongly implicated nucleic acid–
sensing TLRs in the activation of autoreactive B cells, pDCs, and 
other cell types implicated in SLE pathogenesis (9–13). It follows 
that in all murine models of SLE evaluated to date, mice with func-
tional defects in both TLR7 and TLR9, or simply TLR7, have mark-
edly reduced immune activation and end-organ disease (14–23). 
However, quite paradoxically, TLR9 deficiency (TLR9KO) alone 
invariably leads to exacerbated clinical manifestations in these 
same models, despite the fact that functional TLR9 (TLR9WT) is 
required for the production of dsDNA/chromatin-reactive auto-
Abs (15, 24–27). Exactly how the loss of TLR9 can have such a pro-
found impact on disease progression is unclear, especially since 
the resulting autoimmune disorders may reflect a variety of tissue-
specific effector mechanisms.
We have now leveraged the hyperactivity of TLR9-deficient 
mice to develop a T cell–dependent model of systemic autoimmu-
nity. Clinical manifestations of this model depend on the adoptive 
transfer of OVA-specific DO11 T cells into sublethally irradiated 
TLR9KO mice that express a Tg-encoded OVA fusion protein on 
MHC class II+ cells. Remarkably, these mice develop a systemic 
autoimmune disease with severe cutaneous manifestations, but 
only if the recipient is TLR7 sufficient and the DO11 T cells are 
capable of expressing FasL. Gene expression profiling revealed 
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As expected, CFSE-labeled OVA-specific DO11 Tg T cells 
only divide when injected into double-transgenic Ii-TGO 
mice simultaneously administered Dox. Expression of 
either transgene alone was not sufficient to induce division 
(Supplemental Figure 1, A and B; supplemental material 
available online with this article; https://doi.org/10.1172/
JCI98219DS1). Nevertheless, Ii-TGO mice injected with 
naive DO11 T cells showed no evidence of sustained auto-
immunity. However, when Dox-administered Ii-TGO mice 
were sublethally irradiated (Dox/400R) and then injected 
with preactivated T cells, they developed modest sple-
nomegaly and produced autoantibodies (Supplemental 
Figure 1, C and D). Antinuclear antibodies (ANAs) were 
detected by 3 to 4 weeks after T cell injection by immu-
nofluorescent staining of HEp-2 cells. These sera showed 
a predominantly homogeneous nuclear-staining pattern, 
consistent with a role for TLR9. Beyond splenomegaly and 
ANA production, these mice did not exhibit further clinical 
manifestations of autoimmune disease.
TLR9 constrains self-reactivity in Ii-TGO mice. To 
determine whether TLR9 deficiency would lead to a 
more severe disease outcome in this model, we intercrossed Ii-
TGO and BALB/c TLR9-deficient (TLR9KO) mice. Remarkably, 
DO11-injected TLR9KO Ii-TGO mice developed more extensive 
splenomegaly than TLR9-sufficient (TLR9WT) Ii-TGO mice (Fig-
ure 1A) and also began to lose weight (Figure 1B). Comparably 
treated TLR7-deficient (TLR7KO) or TLR7/9 double-deficient 
(TLR7/9DKO) Ii-TGO recipient mice showed no evidence of sple-
nomegaly or weight loss. The inability of DO11 T cells to trigger 
an autoimmune response in the TLR7KO and TLR7/9DKO mice was 
not due to the inability of T cells to engraft or the recipient cells to 
express antigen, as fluorochrome-labeled (VPD450, Violet Prolif-
eration Dye) T cells divided comparably in all genotypes (Figure 
1C). Recipient mice that were not provided with Dox also failed 
to show any signs of autoimmunity. Therefore, the enhanced 
autoimmune response detected in the TLR9KO Ii-TGO recipients 
depended on Dox-induced expression of TGO and the natural 
expression of TLR7 as well as loss of TLR9.
TLR9 deficiency further promotes B cell activation. TLR9KO Ii-
TGO recipients mounted more vigorous B cell responses than 
TLR9WT Ii-TGO recipients, as shown by a higher proportion of 
that FasL is also upregulated in the skin of CLE patients compared 
with healthy controls, while FasL is not upregulated in the skin of 
psoriasis patients. Thus, we have developed a rapidly inducible 
model of cutaneous lupus that allows us to explore the negative 
regulatory role of TLR9 as well as the pathophysiology of CLE.
Results
T cell detection of an OVA fusion protein expressed on MHC class II+ 
cells induces autoantibody production. Mice expressing a mem-
brane-bound OVA Tg have been described previously (28-30). This 
fusion protein, referred to as TGO, incorporates OVA1122–1595 fused 
to the transmembrane and cytoplasmic domains of the transfer-
rin receptor, and therefore TGO efficiently traffics to endocytic 
compartments. The promoter is a Tet-regulated element (TRE), 
so gene transcription depends on the combination of a reverse 
transactivator (rtTA) and doxycycline (Dox). We crossed the TGO 
mice to a Tg line expressing an invariant chain–driven (Ii-driven) 
rtTA (Ii-rtTA) (31), resulting in TGO expression on MHC class 
II+ cells following Dox administration. These double-Tg Ii-TGO 
mice were then backcrossed to BALB/c for over 10 generations. 
Figure 1. TLR9 deficiency promotes systemic autoimmunity and 
B cell activation. TLR9 WT, TLR9KO, TLR7KO, and TLR7/9DKO Ii-TGO 
mice were or were not provided with Dox chow and were suble-
thally irradiated (400R) and injected i.v. with DO11 T cells. (A and B) 
Spleen weight (g) at 4 weeks and total body weight (g) at weekly 
time points following injection. (C) Proliferation of VPD-labeled 
naive DO11 T cells in sdLNs 5 days after T cell injection (n = 5 per 
group). (D) B220+ cells from the sdLNs stained for GC markers Fas 
and GL7. (E) Plasma cells in the bone marrow measured by ELISpot 
assay at 4 weeks after T cell injection (n = 6 per group). (F) Autoan-
tibodies detected by HEp2 staining. Original magnification, ×200. 
Images were captured at ×2 magnification using an ImmunoSpot 
plate reader (CTL), and a representative well image is shown in the 
figure. Data are shown as mean ± SEM and are representative of 
5 independent experiments with n = 20 mice per group (A, B, D, 
and F). ***P < 0.001; ****P < 0.0001, 1-way ANOVA with Šidák’s 
multiple-comparison test.
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TLR9WT recipients, while even fewer DO11 T cells were recov-
ered from the lymphoid tissues of comparably treated TLR7KO 
or TLR7/9DKO Ii-TGO mice (Figure 2A and Supplemental Fig-
ure 2C). In addition, a high proportion of the DO11 T cells from 
the TLR9KO Ii-TGO recipients were Tbet+ and actively produc-
ing IFN-γ, while RORγT and GATA3 were not detected. In con-
trast, there were essentially no cytokine-producing cells in the 
TLR9WT, TLR7KO, or TLR7/9DKO Ii-TGO recipients (Figure 2B and 
Supplemental Figure 2D). Consistent with their Th1 phenotype, 
the T cells in the TLR9KO recipients also expressed significantly 
higher levels of FasL than any of the other groups (Figure 2C). 
TLR9KO recipients also had a greater number of PD1+CXCR5+ 
T follicular helper (TFH) cells in the sdLNs (Figure 2D). These 
studies demonstrate a critical role for recipient TLR expression 
in the determination of T cell function. In the absence of TLR9, 
DO11 T cells differentiate to potent Th1-like effector cells and 
TFH cells through a process dependent on TLR7.
TLR9 deficiency promotes extensive immune activation in the 
skin. Another major difference between TLR9WT and TLR9KO 
Ii-TGO recipients was the presence of skin disease only in the 
TLR9KO mice. By 4 weeks after T cell transfer, the TLR9KO Ii-TGO 
recipients developed severe skin lesions over the entire torso. His-
tological examination revealed many of the features of human 
CLE: perivascular/perifollicular mononuclear infiltrate, fol-
licular plugging, basal layer vacuolar changes, modest basement 
membrane thickening, dermal mucin accumulation, apoptotic 
cell death in the epidermis, and Ab deposition at the dermal/epi-
dermal border (Figure 3, A–G, and refs. 3, 4, 7, 33–35). However, 
there are differences between murine lupus-like skin inflamma-
tion (LLSI) and human CLE skin. The epidermis of mouse skin is 
much thinner at baseline (only 2 layers) and invariably thickens in 
response to inflammation. Therefore, in contrast to human cuta-
neous lupus, which is commonly associated with epidermal atro-
phy, the DO11→TLR9KO Ii-TGO recipients developed epidermal 
hyperplasia, similar to the inflammatory skin disease that occurs 
in SLE-prone MRL/lpr mice (36–38) or in a limited number of 
hypertropic discoid lupus patients (39–42). The TLR9WT, TLR7KO, 
and TLR7/9DKO Ii-TGO recipients showed no evidence of skin 
inflammation, demonstrating that this model of LLSI was also 
dependent on the loss of TLR9 and the expression of TLR7.
Cells were isolated from the shaved dorsal skin of experimental 
mice. FACS analysis of cells isolated from the epidermis revealed 
major differences between the TLR9WT and TLR9KO recipients 
(Figure 4A), consistent with more extensive immune activation in 
the TLR9KO mice. Skin-infiltrating hematopoietic cells were dis-
tinguished from host stromal cells by their expression of CD45, 
and the TLR9KO recipients showed more extensive infiltration of 
hematopoietic cells, as indicated by the percentages of CD45+ 
cells in the total cell suspension (R1). The CD45+ compartment of 
the TLR9KO epidermis included many more CD4+ cells (R3), most 
of which were KJ126+ DO11 T cells. Moreover, the TLR9KO CD11c+ 
cells (R4) were more activated, as shown by increased expression 
of both CD86 and Fas. In addition, approximately 20% of the 
TLR9KO viable CD45neg KCs (R2), expressed MHC class II, while 
very few of the TLR9WT KCs were class II+. These data indicate that 
ongoing inflammation in the skin converted KCs to efficient TGO-
expressing antigen-presenting cells (APCs).
B220+Fas+GL7+ germinal center (GC) B cells in skin-draining 
LNs (sdLNs) and spleen by 4 weeks after T cell injection (Figure 
1D and Supplemental Figure 2A). They also had more ELISpot+ 
plasma cells in the BM and spleen when compared with TLR9WT 
recipients (Figure 1E and Supplemental Figure 2B). As predicted 
from previous studies (20, 32), TLR expression modulated auto-
antibody specificity, as shown by ANA staining patterns on HEp2 
cells; sera from the TLR9WT mice showed a predominantly homo-
geneous nuclear-staining pattern, while the TLR9KO sera routinely 
showed a cytoplasmic staining pattern (Figure 1F). This is an ANA 
pattern associated with SLE (AC-19; International Consensus on 
ANA Patterns, www.anapatterns.org), and we have seen this pat-
tern frequently in mice with predominantly TLR7-driven disease. 
GC+ B cells were not detected in TLR7KO or TLR7/9DKO Ii-TGO 
recipients, and neither of these strains made ANAs, again point-
ing to a critical role for TLR7 in the development of autoimmunity.
TLR9 deficiency promotes OVA-specific T cell activation in Ii-
TGO–expressing recipients. The impact of TLR9 deficiency on 
DO11 T cell expansion and differentiation was evaluated by flow 
cytometry. Both sdLNs and spleens of the TLR9KO recipients 
contained a higher proportion of KJ126+ T cells than those of the 
Figure 2. TLR9-deficiency promotes development of Th1 and TFH cells. 
sdLN suspensions from DO11-injected TLR9WT, TLR9KO, TLR7KO, and 
TLR7/9DKO Ii-TGO mice at 4 weeks after T cell injection were analyzed for 
(A) percentages of DO11 (KJ126+) T cells in the CD4+ gate, (B) percentages 
of cytokine-producing cells in the KJ126+ gate, (C) percentages of FasL-
expressing cells in the KJ126+ gate, and (D) percentages of TFH cells in the 
KJ126+ gate. Data are shown as mean ± SEM and are representative of 5 
independent experiments with n = 15 mice per group. *P < 0.05; **P < 
0.01; ***P < 0.001; ****P < 0.0001, 1-way ANOVA with Šidák’s multiple-
comparison test (A–C) and 2-tailed Student’s t test (D).
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for FasL in cutaneous inflammation. To further explore the 
relevance of FasL to cutaneous disease, we compared the 
disease-inducing activity of FasL-deficient DO11gld T cells 
to DO11 T cells from FasL-sufficient littermates. Remark-
ably, DO11gld T cells did not elicit any overt clinical evidence 
of skin disease (Figure 5A). Nevertheless, the TLR9KO mice 
injected with DO11gld T cells still developed splenomegaly 
and made autoantibodies (Figures 5, B and D), and FACS 
analysis showed evidence of immune activity in the skin 
(Figure 5C). The DO11gld→TLR9KO mice had significantly 
more infiltrating inflammatory monocytes, neutrophils, 
and DO11 T cells compared with DO11→TLR9WT mice (P 
< 0.05) and trended toward more IFN-γ–producing DO11 T 
cells. However, the total number and frequency of inflam-
matory monocytes, granulocytes, DO11 cells, and IFN-γ–
producing DO11 cells was dramatically reduced compared 
with that in the DO11→TLR9KO mice. Together, the data 
point to a critical role for FasL in skin inflammation.
Gene expression profiling points to FasL induction of pro-
inflammatory cytokine and chemokine production. FasL is 
known to provoke both apoptosis and proinflammatory 
cytokine and chemokine production. To better understand 
how FasL deficiency led to such a dramatic reduction in cutane-
ous disease, we compared gene expression patterns in the skin of 
DO11→TLR9WT Ii-TGO (group 1), DO11→TLR9KO Ii-TGO (group 
2), and DO11gld→TLR9KO Ii-TGO (group 3) mice. RNA was isolated 
from total skin biopsies obtained 4 weeks after T cell injection, and 
expression levels were quantified for the 750 genes detected by 
the NanoString murine cancer immune code set. Normalized log2-
transformed values were analyzed with nSolver software 3.0, and 
unbiased hierarchical clustering (heatmap2 software) was used to 
generate the heatmap depicted in Figure 6A. A total of 156 genes 
were increased at least 2-fold in group 2 skin relative to group 1 skin. 
Unexpectedly, most of the genes highly upregulated in the group 2 
skin, compared with the group 1 skin, were also upregulated in the 
group 3 skin (clusters II, III, V, and VII) despite the relatively nor-
mal appearance of the group 3 skin. A more limited subset of genes 
was only upregulated in the group 2 skin and not in the group 3 skin 
(clusters I, IV and VI). The fold change of the group 2 values rela-
tive to the group 1 values and the fold change of the group 3 values 
relative to the group 1 values were further used to classify genes as 
To better preserve markers compromised by the trypsin diges-
tion used for the isolation of epidermal cells, we used a collagenase/ 
hyaluronidase protocol to isolate cells from unseparated epidermis 
and dermis (Figure 4B). Again, there were more KJ126+ CD4 cells 
in the TLR9KO skin (R5), and as in the sdLNs, a significant propor-
tion of DO11 T cells in TLR9KO, but not TLR9WT, recipients were 
making IFN-γ (P < 0.001). Within the CD45+CD11b+ myeloid com-
partment (R6), the TLR9KO skin contained more Ly6Chi inflamma-
tory monocytes (R7), Ly6CInt-Ly6GInt cells (R8), and Ly6C+Ly6Ghi 
granulocytes (R9). These data clearly indicate a causal relation-
ship between infiltrating inflammatory cells and effector T cells 
and CLE-like disease and further point to a critical role for TLR9 
in the negative regulation of this process. The importance of IFN-γ 
to the disease process was shown by the absence of skin disease 
and reduction in other clinical manifestations of mice injected 
with IFN-γ–/– DO11 T cells (Supplemental Figure 3).
FasL is implicated in cutaneous lupus. The presence of FasL-
expressing DO11 cells in the sdLNs of TLR9KO Ii-TGO mice and the 
expression of Fas by KCs, T cells, and myeloid cells pointed to a role 
Figure 3. TLR9 deficiency results in LLSI. (A) Clinical appearance 
of DO11-injected TLR9WT or TLR9KO Ii-TGO mice, provided or not 
provided with Dox chow, at 4 weeks after injection. (B and C) H&E-
stained skin sections showing follicular plugging (black arrow, B), 
perivascular and perifollicular mononuclear infiltrate, vacuolization 
of basal layer (black arrowhead, C), and apoptotic KCs in the epi-
dermis (black arrows, C). Original magnification, ×200 (B); ×400 (C).
(D) Basement membrane thickening shown by PAS stain. Original 
magnification, ×400. (E) Mucin deposition in the dermis detected 
by Alcian blue stain. Original magnification, ×200. (F) TUNEL stain 
showing apoptotic cell death (red) counterstained with DAPI (blue). 
Original magnification, ×200; ×400 (inset). and (G) Ig deposition 
at basement membrane (white arrow) detected by FITC anti-IgG 
(green) and counterstained with DAPI (blue). Original magnifica-
tion, ×200. Images shown are representative of 5 mice per group 
from 3 independent experiments.
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Importance of type I IFN to clinical manifestation of disease. The 
strong IFN signature apparent in the skin could reflect the activ-
ity of IFN-γ and/or elevated levels of type I IFNs. The exacerbated 
disease of TLR9-deficient MRL/lpr mice was previously found to 
depend on type I IFNs (45). To determine the role of type I IFN 
in our model, TLR9KO Ii-TGO mice were injected biweekly with a 
blocking Ab specific for the type I IFN receptor α-chain (IFN-aR) 
(46, 47) or with an isotype control, starting from day –1 relative to T 
cell transfer until the mice were euthanized. Ab treatment dramat-
ically reduced clinical manifestations of disease when compared 
with that of littermates treated with an isotype control (Figure 7, A 
and B). Although the IFN-aR–treated TLR9KO mice still developed 
splenomegaly (Figure 7C), there were major differences in the 
skin-infiltrating cells, as shown by FACS analysis, including signif-
icantly fewer CD45+ hematopoietic cells, DO11 T cells, and pDCs 
in the skin of the IFN-aR–treated mice compared with isotype con-
trol TLR9KO mice (Figure 7, D and E). pDCs are a major source of 
either upregulated in both TLR9KO recipient groups (Figure 6B) or 
preferentially upregulated in group 2 skin compared with group 3 
skin (Figure 6C). Genes highly upregulated in both strains included 
many interferon-stimulated genes (ISGs), such as OAS2, IFITM1, 
IFI44, STAT1, CXCL9, CXCL10, and CXCL11. Genes preferen-
tially upregulated in the group 2 skin included myeloid and neu-
trophil chemokines, such as IL-1β, IL-6, CXCL2 (MIP-2), CXCL1 
(KC), CCL3 (MIP-1α), and CCL4 (MIP-1β), genes previously shown 
to be induced by FasL activation of peritoneal macrophages and 
other cell types (43, 44). A small number of genes were also lower 
in the group 2 skin than the other 2 groups. These included CD207 
(Langerin, indicated by a black arrow in cluster III, Figure 6A). The 
decrease in Langerin transcripts indicates the reduced presence of 
Langerhans cells in the skin. Together, the data demonstrate that a 
remarkably small number of FasL-induced proinflammatory che-
mokines and cytokines are needed to recruit the effector cells that 
mediate actual skin lesions.
Figure 4. DO11 T cell and myeloid cell infiltration in the skin. Representative FACS plots and compiled data of cells isolated from the epidermis (A) or 
combined epidermis/dermis (B) of Dox/400R TLR9WT (left column) or TLR9KO (right column) recipients at 4 weeks after T cell injection. Gating summary: R1, 
CD45+ hematopoietic cells; R2, live KCs; R3, CD45+CD4+ cells; R4, CD45+CD11c+ cells; R5, CD4+ cells in CD45+ gate; R6, CD11b+ cells in CD45+ gate; R7, inflamma-
tory monocytes in CD45+CD11b+ gate; R8, Ly6C-Ly6G intermediate cells in CD45+CD11b+ gate; R9, neutrophils in CD45+CD11b+ gate. Data are shown as mean ± 
SEM and are representative of 3 independent experiments with n = 6 mice per group. *P < 0.05; **P < 0.01; ***P < 0.001, 2-tailed Student’s t test.
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type I IFN in both SLE-prone mice and lupus patients (48, 49) and 
migrate to the skin in patients with CLE (50). Together, the data 
demonstrate a key role for type I IFN in this model.
Relevance to human CLE. To further explore the relevance 
of the DO11Ii-TGO mice to human disease, we compared gene 
expression profiles of lesional skin obtained from subjects with 
CLE or psoriasis to that of healthy controls. Clinical biopsies from 
the skin of patients were identified and confirmed histologically 
to be consistent with a diagnosis of CLE or psoriasis; the patients’ 
charts were reviewed to determine the lupus subtype by clini-
cal presentation, either acute cutaneous lupus (ACLE), subacute 
cutaneous lupus (SCLE), or chronic cutaneous lupus (CCLE). RNA 
isolated from these samples was analyzed using Illumina DASL 
gene array, as described previously (51), and further analyzed 
with a NanoString human cancer immune code set. Gene expres-
sion within human lupus lesional skin revealed key parallels to 
our murine model. Remarkably, FasL expression was significantly 
increased in all SCLE and CCLE subjects (trending toward signifi-
cance in ACLE subjects), but not in psoriasis subjects, verifying 
that its expression is specific for lupus rather than all inflammatory 
skin diseases (Figure 8A). Gene expression data from the human 
NanoString analysis was compared with the murine NanoString 
data by using genes that were more than 2.5-fold upregulated in 
the group 2 mice compared with the group 1 mice and genes that 
were more than 2-fold upregulated in CCLE subjects compared 
with healthy controls. A number of highly upregulated genes in the 
murine code set were not present in the human code set and vice 
versa and hence were excluded from the analyses. However, many 
of the ISGs and chemokines highly upregulated in the murine 
array were also upregulated in the human lupus lesions and, to a 
lesser extent, in the psoriasis lesions (Figure 8B), further support-
ing the relevance of our model to human CLE.
Discussion
Failure to appropriately clear cell debris is a common feature of 
lupus and other related disorders. Nucleic acid sensors, such as 
the endosomal TLRs, then respond to excessive levels of DNA 
and/or RNA by producing type I IFNs and proinflammatory cyto-
kines that promote tissue-specific inflammatory responses. For 
reasons that remain unresolved, TLR9-deficient SLE-prone mice 
invariably develop more severe clinical manifestations than their 
TLR9-sufficient counterparts through mechanisms that depend 
Figure 5. FasL-deficient DO11 T 
cells fail to induce skin lesions. 
DO11 or DO11gld T cell–injected 
Dox/400R TLR9WT or TLR9KO Ii-
TGO recipients were evaluated 4 
weeks after injection. (A) Clinical 
appearance (upper row) and skin 
histology by H&E staining. Original 
magnification, ×100 (middle row); 
×200 magnification (bottom row). 
Representative images from n = 5 
mice per group. (B) Spleen weights. 
(C) Skin-infiltrating cells, percent-
ages of CD45+ cells in total skin cell 
suspension (left); percentages of 
CD11b+ myeloid cells, CD11b+Ly6C+ 
inflammatory monocytes, and 
CD11b+Ly6G+ neutrophils (cen-
ter); and percentages of CD4+, 
CD4+KJ126+, and KJ126+IFN-γ+ T cells 
(right) within the CD45+ gate. (D) 
Autoantibodies detected by HEp2 
staining and ANA score. Original 
magnification, ×200. Data are 
shown as mean ± SEM and are 
representative of 2 independent 
experiments with n = 8 mice per 
group. *P < 0.01; **P < 0.01; ***P 
< 0.001; ****P < 0.0001, 1-way 
ANOVA and 2-way ANOVA with 
Šidák’s multiple-comparison test.
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on the expression of TLR7. We have now developed a rapid-onset 
inducible model of systemic autoimmunity, dependent on the loss 
of TLR9 and the expression of TLR7, which should facilitate inves-
tigation of the regulatory properties of TLR9. These mice resemble 
other murine models of SLE with regard to splenomegaly, lympho-
cyte activation, and autoantibody production. Fortuitously, they 
also develop severe cutaneous inflammation that recapitulates 
many of the features of human cutaneous lupus.
SLE is considered a type I IFN-driven disease, and SLE 
patients frequently have a strong IFN signature in peripheral 
blood mononuclear cells (PBMCs) (52, 53). pDCs are considered 
a major source of type I IFN in these patients (48). Cells isolated 
from the skin of CLE patients also express an IFN signature attrib-
uted to pDCs that traffic to the skin of these patients (50). Type I 
IFNs have been implicated in the abnormal activation of a variety 
of cell types that contribute to SLE pathogenesis, including the 
generation of IFN-γ–producing CD4+ T effector subsets (54–56). 
DO11→TLR9KO Ii-TGO mice also showed an IFN signature in the 
skin that correlated with high numbers of skin-infiltrating DO11 
IFN-γ–producing effector cells. To determine whether type I IFN 
contributed to the development of skin lesions in our model, we 
treated DO11→TLR9KO Ii-TGO mice with a blocking Ab spe-
cific for IFN-aR (46). This same Ab has been used to prevent dis-
ease onset in SLE-prone BXSB mice (57). We found that IFN-aR 
blockade not only prevented the development of skin disease, 
but also prevented the accumulation of pDCs in the skin. These 
data are consistent with the notion that pDCs play a pivotal role 
in our model of LLSI, but also point to an important type I IFN– 
Figure 6. Gene expression in the 
skin of mice injected with DO11 
or DO11gld T cells. Skin biopsies 
were obtained from TLR9WT 
or TLR9KO Ii-TGO mice injected 
with DO11 or DO11gld T cells. (A) 
Heatmap showing hierarchical 
clustering of the 750 genes in 
the NanoString murine cancer 
immune code set (left) with data 
presented as log2-transformed 
values on a scale of 0 (blue) to 15 
(red). Genes above the threshold 
of mean+2SD of the background 
were considered for analysis. 
Enlarged images of gene clusters 
are designated by arrows (right). 
Small black arrow denotes the 
gene downregulated in group 2 
compared with group 3. (B) Genes 
similarly expressed by groups 2 
and 3 with a fold change of more 
than 2.5 relative to group 1 and 
with P > 0.05 (not significant) 
between groups 2 and 3. (C) 
Genes differentially expressed by 
groups 2 and 3 with fold change 
of more than 2.5 for group 2 
relative to group 1 and P < 0.05 
(significant) between groups 2 
and 3. Group 1, n = 4; group 2,  
n = 4; and group 3, n = 3.
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TLR9KO Ii-TGO mice develop skin lesions, inflammation is not 
self-resolving, perhaps because the cytokine milieu is so strongly 
IFN driven that peripheral Treg expansion is prevented. Deter-
mining whether DO11 Ii-TGO mice can be “cured” by the trans-
fer of exogenously derived DO11 Treg cells will be an important 
direction for future studies.
Although we expected TLR9 deficiency to amplify the overall 
autoimmune response in the Ii-TGO system, we did not anticipate 
the dramatic impact on the skin, as skin lesions are not routinely 
observed in other TLR9-deficient SLE-prone strains. KCs are 
known to express TLR9 (59), upregulate MHC class II in TLR9KO 
Ii-TGO mice, and thereby become a target for skin-infiltrating 
DO11 effector cells (60). MHC class II expression is a sign of 
activation, and activated KCs make T cell chemokines such as 
CXCL9, CXCL10, and CXCL11 (61), genes that are upregulated in 
the skin of DO11→TLR9KO Ii-TGO mice (Figure 6). The recruit-
ment of DO11 Th1 cells to the skin can then presumably drive a 
chronic response by provoking continuous KC death and poten-
tially KC chemokine/cytokine production. KCs also make their 
own unique form of type I IFN, IFN-κ, which may also contribute 
to the strong Th1 phenotype of the infiltrating T cells (7). Whether 
TLR9 deficiency in KCs per se contributes to disease amplification 
will need to be addressed through the analysis of Ii-TGO mice with 
KC-specific deletion of TLR9.
TLR9 deficiency clearly has a profound effect on the differen-
tiation of DO11 T cells, leading to the specific expansion of Th1 
T cells in both the skin and sdLNs. Exactly how TLR9 deficiency 
regulates T cell fate remains unresolved. It has been proposed that 
TLR9 and TLR7 compete for binding with Unc93b1 and that the 
absence of TLR9 results in a stronger TLR7 response that would 
be more likely to elicit a pathogenic response (62, 63). This idea 
is supported by published studies in immortalized cell lines and 
BM-derived macrophages, but not in BM-derived DCs or B cells 
(64, 65). It is also possible that TLR9 uniquely activates negative 
regulators of innate immune responses or contributes to the clear-
ance of cell debris (66, 67). It has recently been reported that B 
cells from SLE patients are hyporesponsive to TLR9, but not TLR7, 
ligands (68). The role of TLR9 in SLE in additional cell types con-
tinues to be an active area of investigation by our lab and others, 
and the DO11→Ii-TGO model is likely to serve as a useful tool for 
addressing this topic. A better understanding of the cell type(s) 
directly affected by TLR9 deficiency, under competitive condi-
tions, should enable us to focus attention on the most relevant 
effector population(s). Published studies implicate TLR9KO B cells, 
but do not rule out a potential contribution of additional TLR9KO 
APCs or phagocytic cells.
dependent feedback loop in the recruitment and/or maintenance 
of pDCs in the skin.
Our model depends on a membrane-bound OVA fusion pro-
tein, TGO, that incorporates the transmembrane and cytosolic 
domains of the transferrin receptor and therefore constitutively 
cycles to the endocytic compartment. Previous studies have 
shown that DO11 × TGO mice have a high frequency of Tregs in 
both the thymus and peripheral lymphoid tissue that is not seen in 
TGOneg DO11 mice (28). Therefore, it is highly likely that thymic 
epithelial cells express low levels of TGO, even in the absence of 
Dox, and this results in mice that are essentially TGO tolerant. In 
this context, TGO can be considered a pseudo-autoantigen. This 
level of tolerance needs to be maintained in order to prevent the 
development of autoimmune responses. In fact, in order to initi-
ate a response in our Ii-TGO mice, we needed to transfer activated 
T cells and use sublethally irradiated Ii-TGO recipients. Sublethal 
irradiation is thought to create “space” for lymphocyte expan-
sion, but may also lead to the accumulation of cell debris and the 
production of proinflammatory chemokines that further promote 
a break in tolerance. In contrast, previous studies by Gratz et al. 
have shown that the injection of naive DO11 T cells into Dox-
treated K5-TGO mice, where TGO expression is limited to KCs, 
results in acute inflammation in the skin that then resolves sponta-
neously with the expansion of peripherally derived Tregs (58). The 
inability of naive T cells to induce autoimmunity in Ii-TGO mice 
suggests that, under homeostatic conditions, TGO expression by 
MHC class II+ cells plays an important role in maintaining a state 
of tolerance to self-antigens. However, once DO11→Dox/400R 
Figure 7. Type I IFN blockade abrogates skin disease in TLR9KO Ii-TGO 
mice. (A) Development of skin disease in TLR9KO mice or TLR9KO mice 
treated with anti–IFN-aR mAb or isotype control mAb. (B) Representative 
images at 5 weeks after T cell injection. (C) Spleen weights of experimen-
tal and unmanipulated (no T cells or mAb) controls. (D) Percentages of 
CD4+ and CD4+KJ126+ cells in CD45+ skin cell gate. (E) Representative FACS 
plots and compiled data showing percentages of CD11c+PDCA1+ pDCs in 
CD45+CD11b–CD11c+ skin cell gate. Data are shown as mean ± SEM from 2 
independent experiments and are representative of n = 6 mice per group. 
**P < 0.01; ***P < 0.001; ****P < 0.0001, 2-tailed Student’s t test and 
2-way ANOVA with Šidák’s multiple-comparison test.
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ligands through engagement of the receptor for 
advanced glycation end products (RAGE) and 
perhaps other receptors (75, 76). These studies 
involved assay systems that measured immu-
nostimulatory effects of DNA/TLR9 engage-
ment. However, as discussed, in the context 
of murine models of SLE, TLR9 deficiency 
exacerbates disease outcome. Remarkably, 
RAGE-deficient B6/lpr mice also develop more 
severe nephritis (77). Whether FasL-induced 
HMGB1, under the appropriate conditions, can 
also contribute to a TLR9-mediated negative 
feedback loop is yet one more question that 
can be addressed in future studies. It is well 
known that both Fas and FasL deficiency can 
result in systemic autoimmunity with features 
of SLE, and it has been assumed these models 
reflect the failure of autoreactive T cells or B 
cells to undergo apoptosis. However, Siegel et 
al. have recently shown that mice expressing 
a Fas mutant that is incapable of moving into 
lipid rafts and transmitting an apoptotic signal 
do not develop any indications of lymphopro-
liferative disease or autoimmunity (78). It follows that autoim-
munity in Fas and FasL-deficient mice is not due to the failure of 
FasL to induce apoptosis. Whether FasL can induce the release of 
HMGB1 from other cells that might negatively regulate autoim-
mune responses remains to be determined.
In summary, we have developed a murine model that reca-
pitulates many of the features of CLE, including histological 
changes, a dominant role for Th1 FasL–producing effector cells, 
a strong IFN signature, production of myeloid chemokines, and 
the recruitment of pDCs and inflammatory monocytes to the skin. 
Importantly, this LLSI depends on the transfer of DO11 T cells 
into sublethally irradiated recipients. Irradiation may provide 
an open niche for T cell expansion, eliminate host OVA-specific 
Tregs, and/or lead to the release of cell debris. This model is like-
ly to prove useful for mechanistic studies addressing the role of 
TLR9, TLR7, IFN-γ, FasL, type I IFNs, and other immune media-
tors in CLE and for assessing a variety of therapeutic strategies for 
the treatment of SLE. Small-molecule FasL inhibitors are under 
development and have been shown to be highly effective in the 
blockade of FasL-dependent ocular disorders (73). Related com-
pounds may eventually be appropriate for the treatment of FasL- 
dependent lupus–associated skin disease.
Methods
Mice. BALB/c mice expressing the OVA fusion protein TGO under the 
control of a TRE have been described previously (28). Mice express-
ing an Ii-rtTA (31) were provided by C. Benoist (Harvard Medical 
School, Boston, Massachusetts, USA) and then backcrossed for over 
10 generations to a BALB/c background (Jackson Laboratory). The 2 
lines were intercrossed to generate the original Ii-TGO line. BALB/c 
Tlr9–/– (TLR9KO) and BALB/c Tlr7–/– (TLR7KO) mice (79) were then 
used to generate TLR9KO Ii-TGO and TLR7KO Ii-TGO mice, which 
were in turn used to generate the Ii-TGO TLR7/9 double-knockout 
(TLR7/9DKO) mice. DO11gld mice have been described previously (80). 
Th1 functional analyses routinely focus on IFN-γ. Certainly, 
IFN-γ plays an important role in macrophage activation during 
host defense. Moreover, a number of recent studies have identified 
a critical role for IFN-γ in GC responses (69, 70), and we consis-
tently detect robust GC responses in our DO11→TLR9KO Ii-TGO 
mice. A substantial subset of Th1 cells also express FasL, and FasL 
mediates a range of effector functions that can also contribute to 
lupus pathology, including the induction of apoptosis as well as the 
production of proinflammatory cytokines (71, 72). Nevertheless, 
the complete absence of skin lesions in TLR9KO Ii-TGO recipients 
of FasL-deficient T cells was not anticipated. KCs express reason-
ably high levels of Fas, and the large number of potential KC tar-
gets could explain the skin-centric phenotype of Ii-TGO mice. Fas 
is also upregulated by many of the CD11b+ cells that infiltrate the 
skin, providing additional targets for FasL+ T cells. However, the 
gene expression data strongly suggest that FasL induction of proin-
flammatory chemokines is also a key factor. Most genes upregulat-
ed in the skin of DO11→TLR9KO versus DO11→TLR9WT mice were 
also upregulated in the skin of DO11gld→TLR9KO mice, and these 
included the majority of IFN-inducible genes. The limited set of 
genes that distinguished DO11→TLR9KO from DO11gld→TLR9KO 
skin included many of the myeloid and neutrophil chemokines 
induced in FasL-stimulated macrophages and other cell types 
(43, 44). Importantly, FasL is upregulated in the skin of CLE, but 
not psoriasis, patients. Small-molecule FasL inhibitors are under 
development and have been shown to be highly effective in the 
blockade of FasL-dependent ocular disorders (73). Related com-
pounds may eventually be appropriate for the treatment of FasL-
dependent lupus-associated skin disease.
There may also be a connection between FasL and TLR9. 
In addition to the proinflammatory chemokines listed above, 
FasL has also been shown to induce the rapid release of HMGB1 
through an IRAK4-dependent mechanism (74). HMGB1 has been 
further shown to bind to DNA and enhance responses to TLR9 
Figure 8. Gene expression in human CLE. (A) Microarray analysis showing FasL transcript 
levels in healthy control skin. n =13. CLE patient skin (ACLE, n = 7; SCLE, n = 12; CCLE, n = 6) 
and psoriasis patient skin (n = 17). ***P < 0.001. Benjamini-Hochberg procedure was used for 
multiple comparisons. (B) Fold change of gene expression levels, determined by NanoString 
analysis, of CCLE, SCLE, and psoriasis lesional skin biopsies relative to healthy control skin 
biopsies. Genes above background (mean + 2SD of negative controls) with fold change of 2.0 or 
above and P < 0.05 in CCLE relative to healthy controls were selected and compared with genes 
with fold change greater than 2.5 and P < 0.05 in DO11→TLR9KO (group 2) mice relative to control 
DO11→TLR9WT (group 1) Ii-TGO mice. n = 3 each of CCLE, SCLE, psoriasis subjects, and healthy 
controls. Benjamini-Yekutieli procedure was used for multiple comparisons.
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tured on an Olympus BX51 microscope (NIS Elements imaging soft-
ware version 3.10) at ×100, ×200, and ×400 magnification.
Immunofluorescence. Skin tissue was snap-frozen in OCT (Tis-
sueTek) medium. For Ig staining, 5 μm cryostat sections were fixed 
in cold acetone, blocked with 5% goat serum in 1% BSA/0.1% Tween 
20, and incubated with anti-mouse IgG DyLight-488 Ab (Poly4053, 
BioLegend) for 1 hour. Nuclei were counterstained and mounted with 
ProLong Gold Antifade with DAPI (Life Technologies). Images were 
captured on a Zeiss LSM 700 confocal microscope at ×200 magnifi-
cation. For TUNEL staining, 5 μm paraffin-embedded skin sections 
were processed per the manufacturer’s instructions (In Situ Cell Death 
Detection Kit, TMR red, MilliporeSigma). Nuclei were counterstained 
and mounted with ProLong Gold Antifade with DAPI (Life Technolo-
gies). Images were captured on a Zeiss LSM 700 confocal microscope 
at ×200 and ×400 magnification.
Cell isolation from skin. Cells were isolated from the epidermis or 
combined epidermis/dermis as described previously (30, 83). Briefly, 
to isolate cells from the epidermis, shaved torsal skin was harvested, 
lightly defatted, and incubated in 2 ml Trypsin-EDTA (0.5%, ×10, 
Thermo Fisher) at 37°C for 1 hour. Using forceps, epidermal cells were 
scraped off into a petri dish containing 10% cRPMI. Cell suspension 
was filtered through a 100 μm filter, washed with cRPMI, and stained 
for flow cytometry. To isolate cells from combined epidermis and 
dermis, shaved torsal skin was harvested, minced, and digested for 
45 minutes at 37°C with 2.0 mg/ml collagenase XI from Clostridium 
histolyticum (Sigma-Aldrich), 0.5 mg/ml hyaluronidase from bovine 
testes (Sigma-Aldrich), and 0.1 mg/ml DNAse (Sigma-Aldrich). Single 
cells were washed with 10% cRPMI, filtered through a 100 μm filter, 
and stained for flow cytometry or cultured for intracellular cytokine 
staining as described above.
Gene expression analysis. For mouse NanoString analysis, skin 
biopsies from mice were harvested and stored in RNAlater (QIAGEN) 
overnight at 4°C and then transferred to –80°C until processed with the 
RNeasy Mini Kit (QIAGEN) per the manufacturer’s instructions. RNA 
was quantified using a Nanodrop ND-1000 spectrophotometer (Ther-
mo Fisher Scientific). For RNA analysis, 100 ng total RNA was hybrid-
ized to a NanoString cancer immune code set of 750 genes according to 
the manufacturer’s protocol (NanoString Technologies Inc.). The gene 
expression data were normalized to a set of 6 internal positive and 8 
internal negative controls and then to 20 housekeeping genes. Values 
above the threshold (mean + 2SD of the negative controls) were consid-
ered for analysis. Normalized log2-transformed values were analyzed 
using nSolver analysis software 3.0, and unbiased hierarchical clus-
tering was used to generate the heatmap in the open-source R-based 
software (heatmap2) at UMMS. Genes significantly upregulated in 
group 2 and group 3 and with a fold change value of 2.5 or above rela-
tive to group 1 were further analyzed and classified into genes with P > 
0.05 and genes with P < 0.05 between groups 2 and 3. The Benjamini- 
Yekutieli procedure was used to calculate the FDR for analysis.
For human NanoString and microarray analysis, the UMass 
Memorial (Worcester, Massachusetts, USA) surgical pathology data-
base (https://www.umassmed.edu/pathology/diagnostic/surgical-
pathology/) was queried for FFPE biopsies between 1997 and 2011, and 
each case was reviewed to verify the diagnosis. ACLE, SCLE, CCLE, 
and psoriasis samples were identified. Control skin was acquired from 
“dog ears” resulting from excisions in the dermatology clinic. After 
sample identification, medical records were reviewed to confirm a 
BALB/c DO11 mice (C.Cg-Tg [DO11.10]10 Dlo/J; Jackson Laboratory) 
and BALB/c IFN-γ–/– mice (C.129S7 [B6]-Ifngtm1Ts/J; Jackson Labora-
tory) were used to generate DO11 IFN-γ–/– mice.
In vitro culture and adoptive transfer of T cells. Magnetic bead- 
purified DO11 CD4+ T cells (BD IMag magnetic particles) were activat-
ed using OVA peptide–pulsed (323-339, GenScript) irradiated spleen 
cells (as source of APCs) as described previously (81). 107 T cells were 
injected i.v. into sublethally irradiated (4 Gy) age- and sex-matched 
TLR9WT, TLR9KO, TLR7KO, and TLR7/9DKO Ii-TGO recipient mice. To 
induce expression of the TGO transgene in the MHCII cells, mice were 
fed with 200 mg/kg of Dox chow (Bio-Serv).
VPD450-labeled cell-proliferation assay. DO11 CD4+ T cells were 
labeled with Violet Proliferation Dye (BD Horizon) at a final concen-
tration of 3.5 μM/1 × 107 cells/ml PBS and incubated for 5 minutes in 
a 37°C water bath, followed by quenching with 10% complete RPMI 
1640 medium (cRPMI). 107 VPD-labeled T cells were injected i.v. into 
age- and sex-matched TLR9WT, TLR9KO, and TLR7/9DKO Ii-TGO recipi-
ent mice that were or were not fed with Dox. At day 5 after T cell injec-
tion, mice were euthanized and T cell proliferation in the sdLNs was 
analyzed by flow cytometry.
Flow cytometry. Single-cell suspensions obtained from spleen, 
sdLNs, and skin were analyzed by flow cytometry using fluorochrome-
conjugated mAbs to mouse CD4 (clone RM4-5, Tonbo Biosciences), 
DO11 TCR (clone KJ126, BD Biosciences), CD45R/B220 (clone RA3-
6B2, Tonbo Biosciences), CD95 (clone Jo2, BD Biosciences), GL-7 
(clone GL-7, eBioscience), CD11b (clone M1/70, BioLegend), Ly6C 
(clone 1A8, BioLegend), Ly6G (clone 1A8, BioLegend), CD11c (clone 
N418, BioLegend), CD45 (clone 30-F11, eBioscience), CD86 (clone 
GL1, BioLegend), MHCII (clone I-A/I-E, BioLegend), FasL (clone 
MFL3, BD Biosciences), CXCR5 (clone SPRCL5, BioLegend), CD279/
PD1 (clone RMP1-30, BioLegend), and CD317/PDCA1 (clone 129c1, 
BioLegend). Fixable viability dye (ef780, eBiosciences) and Ghost Dye 
Violet 510 (TONBO Biosciences) were used to distinguish live and 
dead cells. Intracellular staining was carried out on cells preincubated 
with PMA (Sigma-Aldrich), ionomycin (Sigma-Aldrich), and GolgiPlug 
(BD Biosciences) for 4 hours. Cells were permeabilized and fixed with 
eBioscience FOXP3/transcription factor staining buffer (Invitrogen) 
and subsequently incubated with fluorochrome-conjugated mAb to 
mouse IFN-γ (clone XMG1.2, eBioscience), IL17a (clone ebio17B7, 
eBioscience), Tbet (clone ebio-4B10, eBioscience), GATA3 (clone 
TWAJ, eBioscience), and RORγT (clone B2D, eBioscience). Flow 
cytometric analysis was carried out using a BD LSR II with FACSDiva 
software (BD Biosciences), and analysis was conducted with FlowJo 
software 9.7.6 (TreeStar).
ANAs. ANAs were detected by immunofluorescence staining of 
HEp-2 antigen substrate slides (MBL Bion). Bound Ab was detected 
with DyLight 488–coupled goat anti-mouse IgG Ab (Poly4053, Bio-
Legend). Images were captured on a Nikon E600 microscope (NIS 
Elements imaging software version 4.3) at ×200 magnification.
ELISpot assay. Ab-forming cells were detected with 96-well mul-
tiscreen filter plates that were coated overnight at 4°C with 5 μg/ml 
polyclonal goat-anti mouse κ (Southern Biotech) and processed as 
described previously (64).
Histology. Histologic inflammation was assessed in formalin-fixed 
paraffin-embedded (FFPE) skin biopsy specimens from mice. Sec-
tions of 5 μm were deparaffinized and stained with H&E, periodic 
acid-Schiff stain (PAS) and Alcian blue stain (82). Images were cap-
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Study approval. The identification and acquisition of FFPE samples 
from ACLE, SCLE, CCLE, and psoriasis patient skin were approved 
by the Institutional Review Board at the University of Massachusetts 
Medical School. Mice were bred and maintained in the Department of 
Animal Medicine of the University of Massachusetts Medical School 
in accordance with the regulations of the American Association for the 
Accreditation of Laboratory Animal Care. All protocols were approved 
by the Institutional Animal Care and Use Committee.
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classical clinical presentation as well as to determine the clinical lupus 
subtype. All samples were deidentified before use in experiments. 
For gene expression analysis, human skin biopsies were processed 
as described earlier (51). Briefly, RNA was extracted with the High 
Pure RNA Paraffin Kit (Roche) and analyzed by Illumina Bioanalyzer. 
HumanHT-12 v4.0 Whole-Genome DASL HT Assay (Illumina Inc.) 
was used for microarray gene expression profiling of FFPE human 
samples according to the manufacturer’s instructions. RNA isolation 
from FFPE sections, quality control, and subsequent Whole-Genome 
DASL HT assay were performed by the Genomics Core Facility at the 
Wistar Institute (Philadelpia, Pennsylvania, USA). Microarray data 
were normalized, transformed, and presented as base 10 values. Mul-
tiple comparisons were done using the Benjamini-Hochberg (FDR) 
procedure. All original microarray data were deposited in the NCBI’s 
Gene Expression Omnibus database (GEO GSE109248).
NanoString gene expression data were processed as above using 
the NanoString human cancer immune code set of 730 genes. Twenty 
genes present in the murine cancer immune code set were not pres-
ent in the human array. As per the manufacturer’s recommendations, 
RNA samples were adjusted to input of approximately 100 ng of RNA 
fragments greater than 300 nucleotides, which was then hybridized 
to the cartridge. Further analysis was performed with the nCounter 
Analysis System. Values above the threshold (mean+2SD of the nega-
tive controls) were considered for analysis. Genes with a fold change 
value of 2.0 or above and P < 0.05 relative to the healthy controls were 
compared with the group 2 genes with fold change greater than 2.5 
relative to group 1 mice. The Benjamini-Yekutieli procedure was used 
to calculate the FDR for analysis.
IFN-aR Ab treatment. Anti–IFN-aR (250 μg) (MAR1-5A3) (46) or 
isotype control Ab was injected i.p. into 400R/Dox TLR9KO Ii-TGO 
mice (n = 6 mice per group) twice a week starting on the day of T cell 
injection and continuing until mice were euthanized. The murine 
anti–IFN-aR Ab clone 5A3 and control murine IgG1 Ab clone 1A7 were 
produced and provided by MedImmune. Clinical monitoring for the 
development of skin lesions was performed until the mice were euth-
anized for analysis at 5 weeks after T cell transfer. A 4-point clinical 
scoring scale was used to quantify skin disease based on the clinical 
parameters of scaling, alopecia, and erythema, which were each given 
a score of 0–4. Scores for individual clinical parameters were summed 
for each mouse.
Statistics. Statistical analyses were performed using Prism software 
version 7.0 (GraphPad). Experiments are reported as mean ± SEM. Data 
were analyzed using a 2-tailed Student’s t test for comparison between 
2 data sets. Multiple comparisons were analyzed by 1-way ANOVA and 
2-way ANOVA, followed by Šidák’s multiple-comparison post hoc test. 
Differences were considered significant at a P value of less than 0.05.
 1. Kirchhof MG, Dutz JP. The immunopathology of 
cutaneous lupus erythematosus. Rheum Dis Clin 
North Am. 2014;40(3):455–474.
 2. Hejazi EZ, Werth VP. Cutaneous lupus erythema-
tosus: an update on pathogenesis, diagnosis and 
treatment. Am J Clin Dermatol. 2016;17(2):135–146.
 3. Achtman JC, Werth VP. Pathophysiology of cuta-
neous lupus erythematosus. Arthritis Res Ther. 
2015;17:182.
 4. Stannard JN, Kahlenberg JM. Cutaneous lupus 
erythematosus: updates on pathogenesis and 
associations with systemic lupus. Curr Opin 
Rheumatol. 2016;28(5):453–459.
 5. Jabbari A, et al. Dominant Th1 and minimal Th17 
skewing in discoid lupus revealed by transcrip-
tomic comparison with psoriasis. J Invest Derma-
tol. 2014;134(1):87–95.
 6. Tsokos GC. Systemic lupus erythematosus.  
N Engl J Med. 2011; 365(22):2110–2121.
 7. Stannard JN, et al. Lupus skin is primed for IL-6 
inflammatory responses through a keratinocyte-
mediated autocrine type i interferon loop. J Invest 
Dermatol. 2017;137(1):115–122.
 8. Furukawa F, Tanaka H, Sekita K, Nakamura T, 
Horiguchi Y, Hamashima Y. Dermatopathologi-
cal studies on skin lesions of MRL mice. Arch 
Dermatol Res. 1984;276(3):186–194.
 9. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beau-
dette BC, Shlomchik MJ, Marshak-Rothstein A. 
Chromatin-IgG complexes activate B cells by 
dual engagement of IgM and Toll-like receptors. 
Nature. 2002;416(6881):603–607.
 10. Lau CM, et al. RNA-associated autoantigens acti-
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
2 9 7 7jci.org   Volume 128   Number 7   July 2018
vate B cells by combined B cell antigen  
receptor/Toll-like receptor 7 engagement.  
J Exp Med. 2005;202(9):1171–1177.
 11. Viglianti GA, Lau CM, Hanley TM, Miko BA, 
Shlomchik MJ, Marshak-Rothstein A. Activation 
of autoreactive B cells by CpG dsDNA. Immunity. 
2003;19(6):837–847.
 12. Rawlings DJ, Schwartz MA, Jackson SW, Meyer-
Bahlburg A. Integration of B cell responses 
through Toll-like receptors and antigen recep-
tors. Nat Rev Immunol. 2012;12(4):282–294.
 13. Elkon KB, Wiedeman A. Type I IFN system in the 
development and manifestations of SLE. Curr 
Opin Rheumatol. 2012;24(5):499–505.
 14. Berland R, et al. Toll-like receptor 7-dependent 
loss of B cell tolerance in pathogenic autoantibody 
knockin mice. Immunity. 2006;25(3):429–440.
 15. Christensen SR, Shupe J, Nickerson K, Kashgar-
ian M, Flavell RA, Shlomchik MJ. Toll-like recep-
tor 7 and TLR9 dictate autoantibody specificity 
and have opposing inflammatory and regulatory 
roles in a murine model of lupus. Immunity. 
2006;25(3):417–428.
 16. Ehlers M, Fukuyama H, McGaha TL, Aderem 
A, Ravetch JV. TLR9/MyD88 signaling is 
required for class switching to pathogenic 
IgG2a and 2b autoantibodies in SLE. J Exp Med. 
2006;203(3):553–561.
 17. Groom JR, et al. BAFF and MyD88 signals pro-
mote a lupuslike disease independent of T cells.  
J Exp Med. 2007;204(8):1959–1971.
 18. Kono DH, et al. Endosomal TLR signaling is 
required for anti-nucleic acid and rheumatoid 
factor autoantibodies in lupus. Proc Natl Acad Sci 
U S A. 2009;106(29):12061–12066.
 19. Lee PY, et al. TLR7-dependent and FcγR-
independent production of type I inter-
feron in experimental mouse lupus. J Exp Med. 
2008;205(13):2995–3006.
 20. Nickerson KM, et al. TLR9 regulates TLR7- and 
MyD88-dependent autoantibody production and 
disease in a murine model of lupus. J Immunol. 
2010;184(4):1840–1848.
 21. Santiago-Raber ML, et al. Critical role of TLR7 
in the acceleration of systemic lupus erythe-
matosus in TLR9-deficient mice. J Autoimmun. 
2010;34(4):339–348.
 22. Savarese E, et al. Requirement of Toll-like recep-
tor 7 for pristane-induced production of auto-
antibodies and development of murine lupus 
nephritis. Arthritis Rheum. 2008;58(4):1107–1115.
 23. Silver KL, Crockford TL, Bouriez-Jones T, Mill-
ing S, Lambe T, Cornall RJ. MyD88-dependent 
autoimmune disease in Lyn-deficient mice. Eur J 
Immunol. 2007;37(10):2734–2743.
 24. Christensen SR, Kashgarian M, Alexopoulou 
L, Flavell RA, Akira S, Shlomchik MJ. Toll-
like receptor 9 controls anti-DNA autoanti-
body production in murine lupus. J Exp Med. 
2005;202(2):321–331.
 25. Lartigue A, et al. Role of TLR9 in anti- 
nucleosome and anti-DNA antibody production 
in lpr mutation-induced murine lupus. J Immu-
nol. 2006;177(2):1349–1354.
 26. Stoehr AD, et al. TLR9 in peritoneal B-1b cells is 
essential for production of protective self- 
reactive IgM to control Th17 cells and severe auto-
immunity. J Immunol. 2011;187(6):2953–2965.
 27. Yu P, et al. Toll-like receptor 9-independent aggra-
vation of glomerulonephritis in a novel model of 
SLE. Int Immunol. 2006;18(8):1211–1219.
 28. Rosenblum MD, Gratz IK, Paw JS, Lee K, Marshak- 
Rothstein A, Abbas AK. Response to self antigen 
imprints regulatory memory in tissues. Nature. 
2011;480(7378):538–542.
 29. Han H, et al. Thymic stromal lymphopoietin 
(TSLP)-mediated dermal inflammation aggra-
vates experimental asthma. Mucosal Immunol. 
2012;5(3):342–351.
 30. Gratz IK, et al. Cutting edge: Self-antigen con-
trols the balance between effector and regula-
tory T cells in peripheral tissues. J Immunol. 
2014;192(4):1351–1355.
 31. van Santen H, Benoist C, Mathis D. A cassette 
vector for high-level reporter expression driven 
by a hybrid invariant chain promoter in transgenic 
mice. J Immunol Methods. 2000;245(1–2):133–137.
 32. Pisitkun P, Deane JA, Difilippantonio MJ, 
Tarasenko T, Satterthwaite AB, Bolland S. 
Autoreactive B cell responses to RNA-related 
antigens due to TLR7 gene duplication. Science. 
2006;312(5780):1669–1672.
 33. Baima B, Sticherling M. Apoptosis in different 
cutaneous manifestations of lupus erythemato-
sus. Br J Dermatol. 2001;144(5):958–966.
 34. Chang LM, et al. Identification and molecular 
analysis of glycosaminoglycans in cutaneous 
lupus erythematosus and dermatomyositis. J His-
tochem Cytochem. 2011;59(3):336–345.
 35. Toberer F, et al. Apoptotic signal molecules in 
skin biopsies of cutaneous lupus erythematosus: 
analysis using tissue microarray. Exp Dermatol. 
2013;22(10):656–659.
 36. Furukawa F, et al. Spontaneous autoimmune 
skin lesions of MRL/n mice: autoimmune 
disease-prone genetic background in relation 
to Fas-defect MRL/1pr mice. J Invest Dermatol. 
1996;107(1):95–100.
 37. Chan OT, Paliwal V, McNiff JM, Park SH, 
Bendelac A, Shlomchik MJ. Deficiency in 
beta(2)-microglobulin, but not CD1, accelerates 
spontaneous lupus skin disease while inhibiting 
nephritis in MRL-Fas(lpr) nice: an example of 
disease regulation at the organ level. J Immunol. 
2001;167(5):2985–2990.
 38. Yang JQ, et al. CD1d deficiency exacerbates 
inflammatory dermatitis in MRL-lpr/lpr mice. 
Eur J Immunol. 2004;34(6):1723–1732.
 39. Arps DP, Patel RM. Cutaneous hypertrophic lupus 
erythematosus: a challenging histopathologic 
diagnosis in the absence of clinical information. 
Arch Pathol Lab Med. 2013;137(9):1205–1210.
 40. Ko CJ, Srivastava B, Braverman I, Antaya RJ, 
McNiff JM. Hypertrophic lupus erythematosus: 
the diagnostic utility of CD123 staining. J Cutan 
Pathol. 2011;38(11):889–892.
 41. Narang T, Sharma M, Gulati N, Kaur A. Extensive 
hypertrophic lupus erythematosus: atypical pre-
sentation. Indian J Dermatol. 2012;57(6):504.
 42. Crowson AN, Magro C. The cutaneous pathology 
of lupus erythematosus: a review. J Cutan Pathol. 
2001;28(1):1–23.
 43. Hohlbaum AM, Gregory MS, Ju ST, Marshak-
Rothstein A. Fas ligand engagement of resident 
peritoneal macrophages in vivo induces apopto-
sis and the production of neutrophil chemotactic 
factors. J Immunol. 2001;167(11):6217–6224.
 44. Brint E, O’Callaghan G, Houston A. Life in the 
Fas lane: differential outcomes of Fas signaling. 
Cell Mol Life Sci. 2013;70(21):4085–4099.
 45. Nickerson KM, Cullen JL, Kashgarian M, Shlom-
chik MJ. Exacerbated autoimmunity in the 
absence of TLR9 in MRL.Fas(lpr) mice depends 
on Ifnar1. J Immunol. 2013;190(8):3889–3894.
 46. Sheehan KC, et al. Blocking monoclonal antibod-
ies specific for mouse IFN-α/β receptor subunit 
1 (IFNAR-1) from mice immunized by in vivo 
hydrodynamic transfection. J Interferon Cytokine 
Res. 2006;26(11):804–819.
 47. Delaney TA, et al. Type I IFNs regulate inflam-
mation, vasculopathy, and fibrosis in chronic 
cutaneous graft-versus-host disease. J Immunol. 
2016;197(1):42–50.
 48. Rönnblom L, Alm GV. A pivotal role for the natu-
ral interferon alpha-producing cells (plasmacy-
toid dendritic cells) in the pathogenesis of lupus. 
J Exp Med. 2001;194(12):F59–F63.
 49. Zhou Z, et al. Phenotypic and functional 
alterations of pDCs in lupus-prone mice. Sci Rep. 
2016;6:20373.
 50. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg 
P, Jahnsen FL. Plasmacytoid dendritic cells (nat-
ural interferon-α/β-producing cells) accumulate 
in cutaneous lupus erythematosus lesions. Am J 
Pathol. 2001;159(1):237–243.
 51. Rashighi M, et al. CXCL10 is critical for the 
progression and maintenance of depigmenta-
tion in a mouse model of vitiligo. Sci Transl Med. 
2014;6(223):223ra23.
 52. Baechler EC, et al. Interferon-inducible gene 
expression signature in peripheral blood cells of 
patients with severe lupus. Proc Natl Acad Sci  
U S A. 2003;100(5):2610–2615.
 53. Bennett L, et al. Interferon and granulopoiesis 
signatures in systemic lupus erythematosus 
blood. J Exp Med. 2003;197(6):711–723.
 54. Jego G, Palucka AK, Blanck JP, Chalouni C, Pas-
cual V, Banchereau J. Plasmacytoid dendritic 
cells induce plasma cell differentiation through 
type I interferon and interleukin 6. Immunity. 
2003;19(2):225–234.
 55. Pascual V, Farkas L, Banchereau J. Systemic lupus 
erythematosus: all roads lead to type I interfer-
ons. Curr Opin Immunol. 2006;18(6):676–682.
 56. Wenzel J, et al. Enhanced type I interferon 
signalling promotes Th1-biased inflammation 
in cutaneous lupus erythematosus. J Pathol. 
2005;205(4):435–442.
 57. Baccala R, Gonzalez-Quintial R, Schreiber RD, 
Lawson BR, Kono DH, Theofilopoulos AN. Anti-
IFN-α/β receptor antibody treatment amelio-
rates disease in lupus-predisposed mice.  
J Immunol. 2012;189(12):5976–5984.
 58. Gratz IK, et al. Cutting edge: memory regula-
tory T cells require IL-7 and not IL-2 for their 
maintenance in peripheral tissues. J Immunol. 
2013;190(9):4483–4487.
 59. Lebre MC, et al. Human keratinocytes express 
functional Toll-like receptor 3, 4, 5, and 9. J Invest 
Dermatol. 2007;127(2):331–341.
 60. Gaspari AA, Katz SI. Induction and functional 
characterization of class II MHC (Ia) anti-
gens on murine keratinocytes. J Immunol. 
1988;140(9):2956–2963.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 9 7 8 jci.org   Volume 128   Number 7   July 2018
 61. Richmond JM, et al. Keratinocyte-derived 
chemokines orchestrate T-cell positioning in 
the epidermis during vitiligo and may serve 
as biomarkers of disease. J Invest Dermatol. 
2017;137(2):350–358.
 62. Fukui R, et al. Unc93B1 restricts systemic lethal 
inflammation by orchestrating Toll-like receptor 
7 and 9 trafficking. Immunity. 2011;35(1):69–81.
 63. Lee BL, et al. UNC93B1 mediates differen-
tial trafficking of endosomal TLRs. Elife. 
2013;2:e00291.
 64. Nündel K, et al. Cell-intrinsic expression of 
TLR9 in autoreactive B cells constrains BCR/
TLR7-dependent responses. J Immunol. 
2015;194(6):2504–2512.
 65. Bossaller L, et al. TLR9 deficiency leads to 
accelerated renal disease and myeloid lineage 
abnormalities in pristane-induced murine lupus. 
J Immunol. 2016;197(4):1044–1053.
 66. Acharya M, et al. αv Integrins combine with LC3 
and atg5 to regulate Toll-like receptor signalling 
in B cells. Nat Commun. 2016;7:10917.
 67. Sindhava VJ, et al. A TLR9-dependent checkpoint 
governs B cell responses to DNA-containing anti-
gens. J Clin Invest. 2017;127(5):1651–1663.
 68. Gies V, et al. Impaired TLR9 responses in B cells 
from patients with systemic lupus erythemato-
sus. JCI Insight. 2018;3(5):96795.
 69. Jackson SW, et al. B cell IFN-γ receptor signal-
ing promotes autoimmune germinal centers 
via cell-intrinsic induction of BCL-6. J Exp Med. 
2016;213(5):733–750.
 70. Domeier PP, et al. IFN-γ receptor and STAT1 
signaling in B cells are central to spontaneous 
germinal center formation and autoimmunity.  
J Exp Med. 2016;213(5):715–732.
 71. Wajant H, Pfizenmaier K, Scheurich P. Non-
apoptotic Fas signaling. Cytokine Growth Factor 
Rev. 2003; 14(1):53–66.
 72. Peter ME, Krammer PH. The CD95(APO-1/
Fas) DISC and beyond. Cell Death Differ. 
2003;10(1):26–35.
 73. Xiao J, Yao J, Jia L, Lin C, Zacks DN. Protective 
effect of Met12, a small peptide inhibitor of fas, 
on the retinal pigment epithelium and photore-
ceptor after sodium iodate injury. Invest Ophthal-
mol Vis Sci. 2017;58(3):1801–1810.
 74. Altemeier WA, Zhu X, Berrington WR, Harlan 
JM, Liles WC. Fas (CD95) induces macrophage 
proinflammatory chemokine production via a 
MyD88-dependent, caspase-independent path-
way. J Leukoc Biol. 2007;82(3):721–728.
 75. Tian J, et al. Toll-like receptor 9-dependent acti-
vation by DNA-containing immune complexes is 
mediated by HMGB1 and RAGE. Nat Immunol. 
2007;8(5):487–496.
 76. Sirois CM, et al. RAGE is a nucleic acid receptor 
that promotes inflammatory responses to DNA.  
J Exp Med. 2013;210(11):2447–2463.
 77. Goury A, et al. Deletion of receptor for 
advanced glycation end products exacerbates 
lymphoproliferative syndrome and lupus 
nephritis in B6-MRL Fas lpr/j mice. J Immunol. 
2015;194(8):3612–3622.
 78. Cruz AC, et al. Fas/CD95 prevents autoim-
munity independently of lipid raft localization 
and efficient apoptosis induction. Nat Commun. 
2016;7:13895.
 79. Bossaller L, et al. TLR9 deficiency leads to 
accelerated renal disease and myeloid lineage 
abnormalities in pristane-induced murine lupus. 
J Immunol. 2016;197(4):1044–1053.
 80. Saff RR, Spanjaard ES, Hohlbaum AM, Marshak-
Rothstein A. Activation-induced cell death limits 
effector function of CD4 tumor-specific T cells.  
J Immunol. 2004;172(11):6598–6606.
 81. Randolph DA, Stephens R, Carruthers CJ, Chap-
lin DD. Cooperation between Th1 and Th2 cells 
in a murine model of eosinophilic airway inflam-
mation. J Clin Invest. 1999;104(8):1021–1029.
 82. Vincent JG, Chan MP. Specificity of dermal 
mucin in the diagnosis of lupus erythematosus: 
comparison with other dermatitides and normal 
skin. J Cutan Pathol. 2015;42(10):722–729.
 83. Ali N, et al. Regulatory T cells in skin facili-
tate epithelial stem cell differentiation. Cell. 
2017;169(6):1119–1129.e11.
